Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BLU-945 |
| Synonyms | |
| Therapy Description |
BLU-945 is a wild-type-sparing 4th generation EGFR inhibitor with activity against EGFR T790M and EGFR C797S, which may block EGFR signaling and lead to tumor growth inhibition (PMID: 35838760). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BLU-945 | BLU 945|BLU945 | EGFR Inhibitor 4th gen 19 | BLU-945 is a wild-type-sparing 4th generation EGFR inhibitor with activity against EGFR T790M and EGFR C797S, which may block EGFR signaling and lead to tumor growth inhibition (PMID: 35838760). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04862780 | Phase Ib/II | BLU-945 BLU-945 + Osimertinib | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | Terminated | USA | NLD | GBR | FRA | ESP | CAN | 4 |